department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

ACETAMINOPHEN AND IBUPROFEN · pharmadog

pharmadog
drugs
ACETAMINOPHEN AND IBUPROFEN

drug · small molecule

patient view →

ACETAMINOPHEN AND IBUPROFEN

updated 2mo ago

by $PRGO PERRIGO Co plc🔗 ChEMBL

community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 18 approved and 81 investigational indications.

targets

CyclooxygenaseFatty-acid amide hydrolase 1Transient receptor potential cation channel subfamily V member 1

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

ACETAMINOPHEN AND IBUPROFEN

trade names

Abdine, Acephen, Acetaminophen, Acetaminophen component of allay, Acetaminophen component of anexsia, Acetaminophen component of anoquan

generic

ACETAMINOPHEN

MOA

Cyclooxygenase inhibitor; Anandamide amidohydrolase inhibitor; Vanilloid receptor opener

indication

Uses temporarily relieves minor aches and pains due to: headache toothache backache menstrual cramps muscular aches minor pain of arthritis

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 8

drugHYDROCODONE BITARTRATE AND ACETAMINOPHEN31 co-mentions · 20 sources
tagApproval20 co-mentions · 10 sources
drugMidol11 co-mentions · 11 sources
drugAdvil11 co-mentions · 11 sources
drugNuprin11 co-mentions · 11 sources
drugOXYCODONE HYDROCHLORIDE AND IBUPROFEN11 co-mentions · 11 sources
drugIBUPROFEN11 co-mentions · 11 sources
tagSmall Molecule10 co-mentions · 10 sources

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 58m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Trials studying ACETAMINOPHEN AND IBUPROFEN

phase2A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participantsrecruitingn=40
phase3A Study of Combogesic® IV (Intravenous) in Pediatric Patients With Acute Painnot yet recruitingn=60
phase1A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesityrecruitingn=50
phase2A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)recruitingn=230
phase3A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)recruitingn=340
phase2Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)recruitingn=60
phase3A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)recruitingn=770
phase3Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)recruitingn=520

more trials →